Ra Pharmctl Inc (RARX) Position Maintained by RA Capital Management LLC
RA Capital Management LLC maintained its position in Ra Pharmctl Inc (NASDAQ:RARX) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,351,808 shares of the company’s stock at the close of the 2nd quarter. Ra Pharmctl comprises about 2.9% of RA Capital Management LLC’s holdings, making the stock its 11th largest holding. RA Capital Management LLC owned 5.98% of Ra Pharmctl worth $25,333,000 as of its most recent SEC filing.
Several other large investors also recently added to or reduced their stakes in RARX. Tekla Capital Management LLC acquired a new stake in shares of Ra Pharmctl in the second quarter valued at about $7,418,000. VHCP Management II LLC increased its position in shares of Ra Pharmctl by 33.6% in the first quarter. VHCP Management II LLC now owns 725,029 shares of the company’s stock valued at $15,436,000 after acquiring an additional 182,529 shares during the last quarter. Numeric Investors LLC acquired a new stake in shares of Ra Pharmctl in the second quarter valued at about $2,484,000. Nexthera Capital LP acquired a new stake in shares of Ra Pharmctl in the second quarter valued at about $1,912,000. Finally, Candriam Luxembourg S.C.A. acquired a new stake in shares of Ra Pharmctl in the second quarter valued at about $1,518,000. 66.26% of the stock is currently owned by institutional investors and hedge funds.
Shares of Ra Pharmctl Inc (NASDAQ:RARX) traded up 2.84% during trading on Friday, reaching $14.49. The company’s stock had a trading volume of 27,125 shares. Ra Pharmctl Inc has a 12 month low of $12.05 and a 12 month high of $24.12. The firm’s market cap is $327.60 million. The stock’s 50 day moving average price is $14.69 and its 200-day moving average price is $14.69.
Ra Pharmctl (NASDAQ:RARX) last issued its quarterly earnings results on Wednesday, August 9th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.06). Equities analysts predict that Ra Pharmctl Inc will post ($2.31) EPS for the current year.
A number of brokerages have weighed in on RARX. Zacks Investment Research raised Ra Pharmctl from a “sell” rating to a “hold” rating in a research report on Tuesday, September 26th. Jefferies Group LLC set a $25.00 price target on Ra Pharmctl and gave the stock a “buy” rating in a research report on Friday, August 25th. Finally, Royal Bank Of Canada began coverage on Ra Pharmctl in a research report on Thursday, September 14th. They set an “outperform” rating and a $21.00 price target on the stock. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $25.60.
COPYRIGHT VIOLATION NOTICE: This article was originally published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.watchlistnews.com/ra-pharmctl-inc-rarx-position-maintained-by-ra-capital-management-llc/1613196.html.
About Ra Pharmctl
Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.
Want to see what other hedge funds are holding RARX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ra Pharmctl Inc (NASDAQ:RARX).
Receive News & Ratings for Ra Pharmctl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmctl Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.